Navidea Biopharmaceuticals (NYSE: NAVB) confirmed FDA approval for Lymphosee, a novel product indicated for use in lymphatic mapping procedures to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE